After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...